Several other equities research analysts have also recently issued reports on SGYP. HC Wainwright set a $7.00 price target on shares of Synergy Pharmaceuticals and gave the stock a buy rating in a research note on Sunday, May 13th. ValuEngine raised shares of Synergy Pharmaceuticals from a strong sell rating to a sell rating in a research note on Monday, May 7th. Oppenheimer reaffirmed a hold rating on shares of Synergy Pharmaceuticals in a research note on Sunday, May 13th. Zacks Investment Research cut shares of Synergy Pharmaceuticals from a hold rating to a sell rating in a research note on Wednesday, May 9th. Finally, BidaskClub cut shares of Synergy Pharmaceuticals from a sell rating to a strong sell rating in a research note on Tuesday, February 6th. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average target price of $8.08.
Synergy Pharmaceuticals opened at $1.66 on Monday, MarketBeat reports. Synergy Pharmaceuticals has a 12-month low of $1.71 and a 12-month high of $1.78. The stock has a market cap of $431.80 million, a price-to-earnings ratio of -1.63 and a beta of 1.22. The company has a debt-to-equity ratio of -3.01, a quick ratio of 2.71 and a current ratio of 3.09.
Synergy Pharmaceuticals (NASDAQ:SGYP) last released its quarterly earnings results on Thursday, May 10th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.01. Synergy Pharmaceuticals had a negative net margin of 773.82% and a negative return on equity of 652.66%. The company had revenue of $8.59 million for the quarter, compared to analysts’ expectations of $11.18 million. During the same period last year, the company earned ($0.30) EPS. The firm’s revenue for the quarter was up 776.5% compared to the same quarter last year. equities research analysts expect that Synergy Pharmaceuticals will post -0.55 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in SGYP. CVI Holdings LLC acquired a new stake in shares of Synergy Pharmaceuticals in the first quarter worth approximately $3,235,000. BlackRock Inc. boosted its position in shares of Synergy Pharmaceuticals by 8.7% in the fourth quarter. BlackRock Inc. now owns 21,998,125 shares of the biopharmaceutical company’s stock worth $49,056,000 after acquiring an additional 1,761,725 shares during the last quarter. Millennium Management LLC boosted its position in shares of Synergy Pharmaceuticals by 2,579.3% in the first quarter. Millennium Management LLC now owns 504,383 shares of the biopharmaceutical company’s stock worth $923,000 after acquiring an additional 485,558 shares during the last quarter. Granite Investment Partners LLC acquired a new stake in shares of Synergy Pharmaceuticals in the fourth quarter worth approximately $632,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of Synergy Pharmaceuticals in the first quarter worth approximately $417,000. 51.70% of the stock is currently owned by institutional investors and hedge funds.
Synergy Pharmaceuticals Company Profile
Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.
Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.